---
title: "Tenon Medical 10-K: Revenue $3.94M, EPS $(1.70)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280849665.md"
description: "Tenon Medical reported fiscal-year revenue of $3.944 million, a 20% increase year-over-year, with a net loss per share of $(1.70). The company improved its gross margin to 60% and narrowed its net loss to $(12.556) million from $(13.673) million the previous year. Revenue growth was driven by higher procedure volume and the SImmetry+ product line. Operating expenses totaled $15.150 million, leading to significant operating losses despite modest declines in R&D and stock-based compensation."
datetime: "2026-03-27T21:25:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280849665.md)
  - [en](https://longbridge.com/en/news/280849665.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280849665.md)
---

# Tenon Medical 10-K: Revenue $3.94M, EPS $(1.70)

Tenon Medical reported fiscal-year revenue of $3.944 million and a net loss per share of $(1.70), driven by higher procedure volume and contribution from the acquired SImmetry+ product line. The company improved gross margin to 60% and narrowed its net loss to $(12.556) million from $(13.673) million the prior year. Operating losses remained significant as operating expenses totaled $15.150 million despite modest declines in R&D and stock-based compensation.

**Financial Highlights**

-   **Revenue**: $3.944 million, up $0.667 million (20%) year-over-year.
-   **Gross Profit**: $2.358 million; gross margin 60% (vs. 52% in prior year).
-   **Loss from Operations**: $(12.792) million; operating expenses $15.150 million.
-   **Net Loss**: $(12.556) million, improved from $(13.673) million in the prior year; includes $0.236 million gain on investments.
-   **Net Loss Per Share of Common Stock**: $(1.70); weighted-average shares outstanding 7.384 million (basic and diluted).

**Business Highlights**

-   **Revenue Growth Drivers**: Higher procedure volume and the addition of SImmetry+ sales contributed to a 20% increase in revenue.
-   **Channel & Product Mix**: Growth reflected expanded direct hospital and clinician sales and broader use across primary, revision, and adjunct fusion procedures.
-   **Brand Momentum**: Continued commercial traction from the national Catamaran launch (October 2022) and the 2025 acquisition of SImmetry+, which broaden clinical offerings and market coverage.
-   **Operational Efficiency**: Improved gross margin driven by production overhead absorption and operating leverage as volumes increased.
-   **Commercial & Clinical Execution**: Ongoing clinician training, commission-driven sales expansion, and clinical study efforts aimed at increasing adoption.

Original SEC Filing: Tenon Medical, Inc. \[ TNON \] - 10-K - Mar. 27, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TNON.US](https://longbridge.com/en/quote/TNON.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)

## Related News & Research

- [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md)
- [Tenon Medical Q1 revenue rises 90% on the back of procedure volume growth](https://longbridge.com/en/news/286151281.md)
- [Coherent Corp. Rocked by Major Insider Stock Move From Company Director](https://longbridge.com/en/news/286343834.md)
- [Lifeward Delays Quarterly Report Amid Deal Accounting](https://longbridge.com/en/news/286586728.md)
- [Forward Industries Q2 revenue rises over 4x, posts $283 mln net loss](https://longbridge.com/en/news/286466469.md)